OXIS concludes marketing agreement with Becton, Dickinson and Co.PORTLAND, Ore.--(BUSINESS WIRE)--Oct. 12, 1995--OXIS International Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :OXIS) today announced it signed an agreement with Becton, Dickinson and Co. for exclusive marketing and manufacturing rights to OXIS' technology for the rapid detection of antibiotic resistance. The initial proprietary compound covered under the agreement utilizes OXIS' cefesone which, in disk format, received Food and Drug Administration clearance for marketing in May 1995. Cefesone is used to identify microbial microbial pertaining to or emanating from a microbe. microbial digestion the breakdown of organic material, especially feedstuffs, by microbial organisms. resistance to certain penicillins and first-generation cephalosporin cephalosporin (sĕf'əlōspôr`ĭn), any of a group of more than 20 antibiotics derived from species of fungi of the genus Cephalosporium and closely related chemically to penicillin. Cephalosporins, e.g. antibiotics by detecting the production of beta lactamase. Becton Dickinson is an internationally recognized manufacturer and distributor of medical products, including microbiology products for use in hospital and clinical reference laboratories, and is a leader in sales of technology for the rapid detection of the beta lactamase enzyme. "OXIS is pleased to enter into this agreement with Becton Dickinson and looks forward to building a strong relationship in this diagnostic products area," said Ann Barker, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of OXIS. OXIS is a drug development and diagnostic company dedicated to the research and development of technologies and products to combat diseases associated with free radicals and reactive oxygen species reactive oxygen species, n molecules and ions of oxygen that have an unpaired electron, thus rendering them extremely reactive. Many cellular structures are susceptible to attack by ROS contributing to cancer, heart disease, and cerebrovascular disease. (ROS ROS, n.pr See reactive oxygen species. ). The company, with headquarters in Portland, has research facilities in Philadelphia and near Paris. CONTACT: OXIS International Inc. Claudia Groth, 503/283-3911 |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion